Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RegeneCyte for Post-COVID Syndrome
NCT05682560Phase 2Completed
- Sponsor
- StemCyte Inc.
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Post COVID-19 Syndrome (PCS) comparing RegeneCyte with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started May 2023; status: completed.
02
Drugs
RegeneCyte
03
Conditions
Post COVID-19 Syndrome (PCS)
Beyond the preview
Go deeper on NCT05682560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682560.